查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997316

肠道疾病检测市场：2026-2032年全球市场预测（依检测方法、产品类型、病原体、检体类型、最终用户和通路划分）

Enteric Disease Testing Market by Test Method, Product Type, Pathogen, Sample Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肠道疾病检测市场价值将达到 42.9 亿美元，到 2026 年将成长至 46.2 亿美元，到 2032 年将达到 74.9 亿美元，复合年增长率为 8.29%。

主要市场统计数据
基准年 2025 42.9亿美元
预计年份：2026年 46.2亿美元
预测年份 2032 74.9亿美元
复合年增长率 (%) 8.29%

全面概述不断发展的肠道疾病检测领域，其中技术、法规和临床需求相互交织，共同塑造诊断策略。

肠道感染疾病检测的驱动力在于快速发现并应对细菌、病毒和寄生虫引起的疫情，这使其处于临床紧迫性和技术创新的交汇点。诊断检查室、医院、研究机构和学术中心正依赖日益多样化的生物化学检验、培养、免疫检测、分子诊断和定序技术。同时，不断发展的法律规范、不断变化的医疗保健环境以及变革性的患者诊疗路径正在重塑检测的检验、应用和整合到常规工作流程中的方式。

技术整合和运作现代化如何重塑诊断路径并加强临床和公共卫生环境中的病原体检测。

肠道传染病检查领域正经历着一场变革，其驱动力包括技术的成熟、工作流程的整合以及人们对监测日益增长的期望。分子诊断正从小众的调查应用转向一线临床工具，聚合酵素链锁反应(PCR) 的各种变体、恒温环型核酸扩增(LAMP) 和即时PCR使得细菌、病毒和寄生虫的检测更加快速灵敏。同时，包括次世代定序和桑格定序在内的定序平台正被整合用于病原体鑑定、集体爆发追踪和抗生素抗药性分析，从而提升了数据分析和生物资讯学在常规临床实践中的作用。

评估 2025 年关税变化将如何影响诊断产业所有相关人员的采购惯例、供应链弹性策略和资本规划。

2025年关税的引入和调整为肠道传染病检查领域的采购和供应链规划带来了新的复杂性。影响进口耗材、设备和某些检查室组件的关税调整迫使製造商和经销商重新评估其筹资策略、调整定价模式并优化库存缓衝，以维持侦测服务的连续性。这些措施对采购週期、资本支出计画以及国内外商品的相对竞争格局产生了连锁反应。

基于详细细分的洞察，揭示了测试方法、产品线、最终用户需求和病原体优先事项之间的交集，从而指导策略投资。

了解细分市场动态对于使产品开发和市场策略与用户需求保持一致至关重要，这涵盖了检测方法、产品类型、最终用户、病原体重点、检体类型和分销管道等各个方面。检测方面的考虑范围广泛，从采用自动化和手动方法的传统生化检测，到包括非选择性和选择性培养基在内的培养技术，再到涵盖化学化学冷光、酵素免疫分析法吸附试验和侧向流动免疫分析等免疫检测方法。分子诊断透过恒温环型核酸扩增、常规PCR和即时PCR平台提供独特的价值提案，而从Sanger定序到次世代定序定序方案则支援对病原体进行详细的表征和监测。

将促进诊断方法采用差异化的区域趋势进行比较，影响采购管道，并塑造供应链韧性策略。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的部署模式、监管流程和供应链结构有显着影响。在美洲，临床检查室和医院系统通常优先考虑快速分子诊断和高通量仪器，以应对大量患者和支持疫情爆发，而监管核准和报销机制则影响新检测方法的部署速度。此外，该地区的检测网路正在投资定序能力以进行监测，从而推动了对耗材和生物资讯解决方案的需求。

市场参与企业透过整合解决方案、策略伙伴关係和以数据为中心的服务来脱颖而出，并实现了持续的临床应用。

肠道传染病检查市场的主要企业正致力于开发整合仪器、耗材和数位化服务的整合解决方案，以提高客户维繫和生命週期价值。拥有成熟免疫检测和分子诊断产品组合的公司正在投资自动化和互联互通技术，以减少工作量并提高结果的可重复性。同时，定序供应商正在开发样品製备盒和简化的生物资讯流程，以降低技术应用门槛。小规模的创新公司则专注于快速照护现场横向流动化验、等温扩增试剂盒或针对难培养标靶的专用培养基等细分领域。

采取切实可行的策略措施，增强製造商和医疗保健系统的韧性，加快部署，并带来可衡量的营运和临床效益。

产业领导企业应采取果断行动，强化价值链，加速数位整合，并使产品系列与终端用户的实际工作流程相契合。首先，供应商多元化和建立紧急库存策略可以降低贸易中断和关税波动带来的风险。其次，投资于仪器、检查室资讯系统和分析平台之间的无缝数据集成，将提高营运效率，并提升高成本仪器的价值提案。

严谨的混合方法研究框架，结合相关人员访谈、技术文献综述和来自多个资讯来源的检验，确保了可靠的见解。

本分析的调查方法结合了定性和定量方法，旨在全面了解肠道传染病检查的发展趋势。主要工作包括对实验室负责人、临床微生物学家、采购负责人和产品经理进行结构化访谈，以了解实际限制、推广应用驱动因素和技术偏好。此外，与分销合作伙伴和服务机构的补充讨论也提供了有关物流、价格压力和售后支援模式的背景资讯。

整合技术、营运和策略主题，以突显实现对肠道感染疾病进行稳健、快速诊断的途径，满足临床和公共卫生需求。

肠道传染病检查领域的特点是技术快速发展、操作复杂以及市场瞬息万变带来的压力，所有这些因素都要求相关人员具备清晰的策略方向。虽然传统方法在病原体检测和抗药性分析中仍然发挥着至关重要的作用，但分子诊断和定序技术已成为及时检测和流行病学调查的必要手段。耗材、设备、软体和服务如今构成了一个相互依存的生态系统，其中一个领域的决策会影响其他领域的整体绩效和价值实现。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肠道疾病检测市场（依检测方法划分）

  • 生物化学检验
    • 自动生化分析
    • 手工生物化学检验
  • 培养方法
    • 非选择性培养
    • 选择性培养
  • 免疫检测
    • 化学冷光免疫检测
    • 酵素免疫分析法
    • 横向流动化验
  • 分子诊断
    • 恒温环型核酸扩增
    • 聚合酵素链锁反应
    • 即时聚合酵素链锁反应
  • 定序
    • 次世代定序
    • 桑格定序

第九章：肠道疾病检测市场：依产品类型划分

  • 消耗品
    • 成套工具
    • 试剂
  • 装置
    • 免疫分析仪
    • 聚合酵素链锁反应（PCR）装置
    • 序列器
  • 软体服务
    • 数据分析软体
    • 维护服务

第十章：以病原体分類的肠道疾病检测市场

  • 细菌病原体
    • 曲状桿菌
    • 大肠桿菌
    • 沙门氏菌
  • 寄生病原体
  • 病毒病原体
    • 腺病毒
    • 诺罗病毒
    • 轮状病毒

第十一章 肠道疾病检测市场：检体类型

  • 血液检体
  • 直肠拭子
  • 粪便检体

第十二章：肠道疾病检测市场：依最终用户划分

  • 学术和临床检查室
  • 诊断检测实验室
  • 医院
  • 研究机构

第十三章：肠道疾病检测市场：依通路划分

  • 直销
  • 销售代理
  • 线上销售

第十四章：肠道疾病检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：肠道疾病检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 肠道疾病检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国肠道疾病检测市场

第十八章：中国肠道疾病检测市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3M Company
  • Abbott Laboratories
  • ALS Limited
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomerica, Inc.
  • bioMerieux SA
  • Bureau Veritas SA
  • Danaher Corporation
  • DiaSorin SpA
  • Eurofins Scientific SE
  • Hardy Diagnostics
  • Hologic, Inc.
  • Intertek Group plc
  • Merck KGaA
  • Meridian Bioscience, Inc.
  • Neogen Corporation
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • QuidelOrtho Corporation
  • Roche Holding AG
  • Romer Labs Division Holding GmbH
  • SGS SA
  • Siemens Healthcare Diagnostics Inc.
  • TechLab, Inc.
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc
Product Code: MRR-732E7CFCB4A5

The Enteric Disease Testing Market was valued at USD 4.29 billion in 2025 and is projected to grow to USD 4.62 billion in 2026, with a CAGR of 8.29%, reaching USD 7.49 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.29 billion
Estimated Year [2026] USD 4.62 billion
Forecast Year [2032] USD 7.49 billion
CAGR (%) 8.29%

A comprehensive orientation to the evolving enteric disease testing environment where technology, regulation, and clinical needs converge to shape diagnostic strategy

Enteric disease testing sits at the intersection of clinical urgency and technological innovation, driven by the need to rapidly detect and respond to bacterial, viral, and parasitic outbreaks. Diagnostic laboratories, hospitals, research institutes, and academic centers rely on an increasingly diverse toolkit that includes biochemical testing, culture-based approaches, immunoassays, molecular diagnostics, and sequencing technologies. In parallel, evolving regulatory frameworks, changing reimbursement environments, and shifting patient pathways are reshaping how assays are validated, adopted, and integrated into routine workflows.

Today's testing ecosystem balances legacy methods such as selective and non-selective culture with modern modalities like real-time polymerase chain reaction and next-generation sequencing. This hybrid landscape requires laboratory managers and clinical leaders to evaluate trade-offs between throughput, sensitivity, turnaround time, and cost of ownership. As a result, purchasing decisions are less about replacing one technology with another and more about creating complementary diagnostic pathways that optimize patient care and surveillance capabilities.

Moreover, the proliferation of multiplex assays, rapid lateral flow formats, and data analysis software is expanding the operational footprint of enteric testing. Consequently, organizations must navigate procurement complexity, training needs, and data management challenges while preserving diagnostic quality and complying with accreditation standards. This introduction frames a marketplace where scientific rigor meets operational pragmatism, and where strategic choices will determine resilience against the next wave of enteric threats.

How technological convergence and operational modernization are redrawing diagnostic pathways and strengthening pathogen detection across clinical and public health settings

The landscape of enteric disease testing is undergoing transformative shifts driven by technological maturation, workflow consolidation, and heightened surveillance expectations. Molecular diagnostics have transitioned from niche research applications to frontline clinical tools, with polymerase chain reaction variants, loop mediated isothermal amplification, and real-time PCR enabling faster, more sensitive detection of bacterial, viral, and parasitic targets. At the same time, sequencing platforms, including next-generation and Sanger approaches, are being integrated for pathogen characterization, outbreak tracing, and antimicrobial resistance profiling, which elevates the role of data analytics and bioinformatics in routine practice.

Concurrently, immunoassays have diversified, as chemiluminescence assays, enzyme linked immunosorbent formats, and lateral flow devices expand point-of-care and laboratory-based testing options. Culture methods remain indispensable for isolate recovery and susceptibility testing, but laboratories increasingly combine culture with rapid molecular confirmation to accelerate case management. The rise of instrument automation and integrated consumable systems is reducing manual workloads, while software and maintenance services are becoming core components of procurement conversations.

These technological shifts are mirrored by operational and market dynamics. End users such as diagnostic laboratories, hospitals, research entities, and academic centers are reconfiguring workflows to accommodate multiplex testing and high-throughput sequencing. Distribution channels are adapting accordingly, with direct sales, distributors, and online platforms each playing distinct roles in meeting demand. Together, these changes are redefining how public health agencies and clinical providers detect, report, and respond to enteric threats.

Assessment of how tariff shifts in 2025 reshaped procurement practices, supply chain resilience strategies, and capital planning across diagnostic stakeholders

The introduction and adjustment of tariffs in 2025 have added a new layer of complexity to procurement and supply chain planning for enteric disease testing. Tariff adjustments affecting imported consumables, instruments, and certain laboratory components have compelled manufacturers and distributors to reassess sourcing strategies, adjust pricing models, and optimize inventory buffers to preserve continuity of testing services. These measures have had ripple effects across procurement cycles, capital expenditure planning, and the relative competitiveness of domestically produced versus imported goods.

Laboratories reliant on specialized reagents, kits, and sequencing consumables experienced pressure to identify alternative vendors or to negotiate long-term supply agreements that mitigate exposure to cost fluctuations. Instrument manufacturers responded by reengineering bills of materials, localizing certain production steps where feasible, and enhancing service offerings to justify total cost of ownership under new tariff environments. Furthermore, distributors diversified logistics routes and consolidated shipments to manage landed costs more effectively.

The tariffs also influenced the strategic calculus for end users considering capital investments. Hospitals and reference labs evaluated the trade-offs between leasing and purchasing equipment, and some accelerated procurement ahead of tariff implementations to avoid near-term cost increases. In parallel, software and maintenance services became more prominent as organizations sought to extract additional value from existing assets rather than pursue immediate hardware upgrades. Overall, the cumulative impact of tariffs has reinforced the importance of supply chain resilience, vendor diversification, and value-based procurement in sustaining enteric testing capabilities.

Deep segmentation-driven insights revealing where test method, product offerings, end-user needs, and pathogen priorities intersect to guide strategic investments

Understanding segmentation dynamics is essential to match product development and go-to-market strategies with user needs across test method, product type, end user, pathogen focus, sample type, and distribution channels. Test method considerations range from traditional biochemical tests with automated and manual approaches to culture techniques encompassing non-selective and selective media, as well as immunoassays spanning chemiluminescence, enzyme linked immunosorbent, and lateral flow formats. Molecular diagnostics present distinct value propositions through loop mediated isothermal amplification, conventional PCR, and real-time PCR platforms, while sequencing options from Sanger to next-generation sequencing support in-depth pathogen characterization and surveillance.

On the product side, consumables such as kits and reagents are core to day-to-day operations, whereas instruments including immuno analyzers, PCR machines, and sequencers represent capital investments that define throughput and capability. Complementing these are software and services, particularly data analysis tools and maintenance programs, which extend instrument uptime and translate raw outputs into actionable insights. End users span academic and clinical laboratories, diagnostic reference centers, hospitals, and research institutes, each with differing procurement cycles, regulatory requirements, and performance expectations.

Pathogen-specific segmentation underscores distinct assay design and clinical priorities: bacterial pathogens like Campylobacter, Escherichia coli, and Salmonella require both culture and molecular confirmation; viral targets such as adenovirus, norovirus, and rotavirus shift emphasis toward sensitive molecular and immunoassay detection; parasitic organisms demand specialized sample processing protocols. Sample types including blood, rectal swabs, and stool each impose upstream handling and nucleic acid extraction considerations that influence assay selection and workflow design. Finally, distribution channels-direct sales, distributors, and online platforms-shape lead times, service levels, and customer engagement models. Mapping these segments against one another reveals where integrated solutions, bundled consumable-instrument-service offerings, and targeted product enhancements can unlock clinical and operational value.

Comparative regional dynamics that drive differentiated adoption of diagnostics, influence procurement pathways, and shape supply chain resilience strategies

Regional dynamics materially influence adoption patterns, regulatory pathways, and supply chain configurations across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinical laboratories and hospital systems often prioritize rapid molecular diagnostics and high-throughput instruments to manage large patient volumes and support outbreak response, while regulatory approvals and reimbursement mechanisms shape the cadence of new test introductions. Laboratory networks in this region also invest in sequencing capabilities for surveillance, which drives demand for consumables and bioinformatics solutions.

Across Europe Middle East & Africa, diverse regulatory environments and heterogeneous healthcare infrastructures create differentiated opportunities for both centralized reference laboratories and decentralized testing models. In many countries, stringent validation requirements underscore the importance of certified reagents and accredited workflows, whereas public health priorities steer investment toward multiplex assays and platforms capable of integrating surveillance data. Distribution strategies must account for complex logistics across multiple jurisdictions and varying procurement practices.

The Asia-Pacific region presents a mix of highly advanced urban centers and rapidly developing laboratory markets, leading to simultaneous demand for cutting-edge sequencing and scalable immunoassay platforms. Local manufacturing hubs in some countries influence supply chain resilience and cost structures, and partnerships with regional distributors can accelerate market access. In all regions, collaborative public-private initiatives, cross-border surveillance programs, and regional procurement frameworks increasingly shape how enteric testing resources are allocated and deployed.

How market participants are differentiating through integrated offerings, strategic partnerships, and data-centric services to capture sustained clinical adoption

Major players across the enteric testing landscape are focusing on integrated solutions that combine instruments, consumables, and digital services to enhance customer retention and lifecycle value. Companies with established immunoassay and molecular portfolios are investing in automation and connectivity to reduce hands-on time and improve result reproducibility, while sequencing providers are advancing library preparation kits and streamlined bioinformatics pipelines to lower technical barriers for adoption. Smaller innovators are concentrating on niche areas such as rapid point-of-care lateral flow assays, isothermal amplification kits, or specialized media for challenging culture targets.

Strategic activity includes partnerships to expand distribution footprints, co-development agreements to accelerate assay validation, and after-sales service enhancements to improve uptime and customer satisfaction. Several firms emphasize hybrid go-to-market models that blend direct engagement with channel partnerships to address heterogeneous end-user preferences. There is also a clear trend toward subscription and service-based offerings that bundle consumables with instruments and software, thereby smoothing revenue streams and deepening customer relationships.

Competitive differentiation increasingly hinges on data capabilities, including interoperability with laboratory information systems, robust data analysis software, and services that translate complex sequencing outputs into clinically relevant intelligence. As stakeholders prioritize rapid diagnostics, scalability, and actionable insights, companies that can deliver end-to-end solutions and demonstrate measurable operational benefits will secure stronger positions in the market.

Actionable strategic moves for manufacturers and health systems to bolster resilience, accelerate adoption, and deliver measurable operational and clinical benefits

Industry leaders should act decisively to strengthen supply chains, accelerate digital integration, and align product portfolios with end-user workflow realities. First, diversifying supplier bases and establishing contingency inventory strategies will mitigate exposure to trade disruptions and tariff volatility. Second, investing in seamless data connectivity between instruments, laboratory information systems, and analytics platforms will unlock operational efficiencies and enhance the value proposition of higher-cost instrumentation.

Third, manufacturers and distributors should consider modular commercial models that combine consumables, instruments, and software services into subscription plans, which can lower barriers to entry for resource-constrained laboratories while providing predictable revenue streams. Fourth, prioritizing assay development that balances sensitivity, turnaround time, and ease of use-especially for common enteric pathogens like Campylobacter, Escherichia coli, Salmonella, norovirus, and rotavirus-will meet both clinical and public health needs. Fifth, targeted investments in training, technical support, and maintenance services will preserve uptime and improve customer satisfaction, particularly in regions with varied laboratory capabilities.

Finally, fostering collaborative relationships with academic centers, public health agencies, and hospital networks will enable co-development of surveillance-focused solutions and validation studies. By implementing these actions, industry leaders can enhance resilience, accelerate adoption of transformative diagnostics, and deliver measurable benefits across clinical and laboratory settings.

A rigorous mixed-methods research framework integrating stakeholder interviews, technical literature review, and cross-source triangulation to ensure credible insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches to gather a comprehensive view of enteric disease testing dynamics. Primary engagements included structured interviews with laboratory directors, clinical microbiologists, procurement professionals, and product managers to capture real-world operational constraints, adoption drivers, and technology preferences. Supplementary discussions with distribution partners and service organizations provided context on logistics, pricing pressures, and after-sales support models.

Secondary research involved a systematic review of regulatory guidance, clinical practice standards, and recent peer-reviewed literature to ensure alignment with validated laboratory procedures and diagnostic performance expectations. Product literature, manufacturer technical specifications, and instrument service manuals were analyzed to evaluate throughput characteristics, consumable dependencies, and integration capabilities. Comparative analysis across test methods, product categories, and end-user types enabled identification of recurring themes, capability gaps, and commercialization pathways.

Data synthesis emphasized triangulation across sources to reconcile differing stakeholder perspectives and mitigate bias. Throughout the process, attention was paid to reproducibility, transparency in data sourcing, and the contextual relevance of findings to clinical laboratories, hospitals, research institutes, and academic centers. This mixed-methods approach supports robust, actionable insights while acknowledging the operational heterogeneity that characterizes enteric disease testing.

A synthesis of technological, operational, and strategic themes highlighting the path to resilient and responsive enteric diagnostics for clinical and public health needs

The enteric disease testing domain is characterized by rapid technological progress, operational complexity, and evolving market pressures that together demand strategic clarity from stakeholders. Traditional methods continue to play a vital role in pathogen recovery and resistance profiling, while molecular and sequencing technologies have become indispensable for timely detection and epidemiologic investigation. Consumables, instruments, software, and services now form an interdependent ecosystem where decisions in one area influence performance and value realization across others.

Regional nuances, tariff-driven procurement adjustments, and the need for resilient distribution strategies underscore the importance of flexible commercial models and strong after-sales capabilities. End users-from centralized reference laboratories to point-of-care settings-require tailored solutions that account for sample types, pathogen targets, and throughput needs. Companies that offer integrated, data-enabled solutions and that invest in partnerships and local support structures will be best positioned to meet these diverse requirements.

Looking ahead, the sector's trajectory will be shaped by continued innovation in assay chemistry, automation, and bioinformatics, alongside concerted efforts to build supply chain resilience and regulatory alignment. The cumulative effect will be a more responsive diagnostic infrastructure that better supports clinical decision-making and public health surveillance for enteric diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enteric Disease Testing Market, by Test Method

  • 8.1. Biochemical Tests
    • 8.1.1. Automated Biochemical Analysis
    • 8.1.2. Manual Biochemical Tests
  • 8.2. Culture Methods
    • 8.2.1. Non Selective Culture
    • 8.2.2. Selective Culture
  • 8.3. Immunoassays
    • 8.3.1. Chemiluminescence Immunoassay
    • 8.3.2. Enzyme Linked Immunosorbent Assay
    • 8.3.3. Lateral Flow Assay
  • 8.4. Molecular Diagnostics
    • 8.4.1. Loop Mediated Isothermal Amplification
    • 8.4.2. Polymerase Chain Reaction
    • 8.4.3. Real Time Polymerase Chain Reaction
  • 8.5. Sequencing
    • 8.5.1. Next Generation Sequencing
    • 8.5.2. Sanger Sequencing

9. Enteric Disease Testing Market, by Product Type

  • 9.1. Consumables
    • 9.1.1. Kits
    • 9.1.2. Reagents
  • 9.2. Instruments
    • 9.2.1. Immuno Analyzers
    • 9.2.2. Polymerase Chain Reaction Instruments
    • 9.2.3. Sequencers
  • 9.3. Software & Services
    • 9.3.1. Data Analysis Software
    • 9.3.2. Maintenance Services

10. Enteric Disease Testing Market, by Pathogen

  • 10.1. Bacterial Pathogens
    • 10.1.1. Campylobacter
    • 10.1.2. Escherichia Coli
    • 10.1.3. Salmonella
  • 10.2. Parasitic Pathogens
  • 10.3. Viral Pathogens
    • 10.3.1. Adenovirus
    • 10.3.2. Norovirus
    • 10.3.3. Rotavirus

11. Enteric Disease Testing Market, by Sample Type

  • 11.1. Blood Samples
  • 11.2. Rectal Swabs
  • 11.3. Stool Samples

12. Enteric Disease Testing Market, by End User

  • 12.1. Academic And Clinical Laboratories
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Enteric Disease Testing Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributors
  • 13.3. Online Sales

14. Enteric Disease Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Enteric Disease Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Enteric Disease Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Enteric Disease Testing Market

18. China Enteric Disease Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. 3M Company
  • 19.6. Abbott Laboratories
  • 19.7. ALS Limited
  • 19.8. Becton, Dickinson and Company
  • 19.9. Bio-Rad Laboratories, Inc.
  • 19.10. Biomerica, Inc.
  • 19.11. bioMerieux SA
  • 19.12. Bureau Veritas SA
  • 19.13. Danaher Corporation
  • 19.14. DiaSorin S.p.A.
  • 19.15. Eurofins Scientific SE
  • 19.16. Hardy Diagnostics
  • 19.17. Hologic, Inc.
  • 19.18. Intertek Group plc
  • 19.19. Merck KGaA
  • 19.20. Meridian Bioscience, Inc.
  • 19.21. Neogen Corporation
  • 19.22. PerkinElmer, Inc.
  • 19.23. QIAGEN N.V.
  • 19.24. Quest Diagnostics Incorporated
  • 19.25. QuidelOrtho Corporation
  • 19.26. Roche Holding AG
  • 19.27. Romer Labs Division Holding GmbH
  • 19.28. SGS SA
  • 19.29. Siemens Healthcare Diagnostics Inc.
  • 19.30. TechLab, Inc.
  • 19.31. Thermo Fisher Scientific Inc.
  • 19.32. Trinity Biotech plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENTERIC DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENTERIC DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ENTERIC DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ENTERIC DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN ENTERIC DISEASE TESTIN